A drug which has previously been shown to trigger cardiac toxicity.

Cardiac effects connected with breast cancer treatment appear lower with dose-dense chemotherapy A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center discovered that breast cancer patients could be treated safely with a dose-dense regimen of regular chemotherapy agents and the antibody trastuzumab , a drug which has previously been shown to trigger cardiac toxicity. Based on the findings, only one 1 http://malegra-fxt.com .4 % of the 70 early-stage breast cancer patients treated with this regimen experienced congestive center failure after 28 months of follow-up.

http://www.malegra-fxt.com

Related StoriesCareFusion to show fresh respiratory solutions at AARC CongressCamels in Kenya contaminated by MERS virus, brand-new study findsPhilips showcases most recent patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015The RespiCardia System is an implantable gadget using small, electric pulses designed to restore more organic breathing patterns in individuals with sleep disordered breathing. This respiratory administration therapy could also improve Heart Failing and patients’ standard of living.